Locoregional therapies for hepatocellular carcinoma: The current status and future perspectives

被引:10
作者
Chen, Jian-Jian [1 ]
Jin, Zhi-Cheng [1 ]
Zhong, Bin-Yan [2 ]
Fan, Wenzhe [3 ]
Zhang, Wei-Hua [1 ]
Luo, Biao [1 ]
Wang, Yu-Qing [1 ]
Teng, Gao-Jun [1 ]
Zhu, Hai-Dong [1 ]
机构
[1] Southeast Univ, Ctr Intervent Radiol & Vasc Surg, Zhongda Hosp, Dept Radiol,Med Sch, Nanjing 210009, Peoples R China
[2] Soochow Univ, Affiliated Hosp 1, Dept Intervent Radiol, Suzhou, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Intervent Oncol, Guangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
combined modality therapy; hepatocellular carcinoma; immune checkpoint inhibitors; locoregional therapy; molecular targeted therapy; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; RANDOMIZED CONTROLLED-TRIAL; INTERNAL RADIATION-THERAPY; VEIN TUMOR THROMBOSIS; RADIOFREQUENCY ABLATION; TRANSARTERIAL CHEMOEMBOLIZATION; CONVENTIONAL CHEMOEMBOLIZATION; LIVER-TRANSPLANTATION; IRRADIATION STENT; ELUTING BEADS;
D O I
10.1002/ueg2.12554
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatocellular carcinoma (HCC) is one of the most common cancers and a leading cause of cancer-related mortality. Locoregional therapies (LRTs) play a crucial role in HCC management and are selectively adopted in real-world practice across various stages. Choosing the best form of LRTs depends on technical aspects, patient clinical status and tumour characteristics. Previous studies have consistently highlighted the efficacy of combining LRTs with molecular targeted agents in HCC treatment. Recent studies propose that integrating LRTs with immune checkpoint inhibitors and molecular targeted agents could provide substantial therapeutic benefits, a notion underpinned by both basic and clinical evidence. This review summarised the current landscape of LRTs in HCC and discussed the anticipated outcomes of combinations with immunotherapy regimens.
引用
收藏
页码:226 / 239
页数:14
相关论文
共 100 条
[61]   Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma [J].
Millonig, Gunda ;
Graziadei, Ivo W. ;
Freund, Martin C. ;
Jaschke, Werner ;
Stadlmann, Sylvia ;
Ladurner, Ruth ;
Margreiter, Raimund ;
Vogel, Wolfgang .
LIVER TRANSPLANTATION, 2007, 13 (02) :272-279
[62]   Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations [J].
Nault, Jean-Charles ;
Sutter, Olivier ;
Nahon, Pierre ;
Ganne-Carrie, Nathalie ;
Seror, Olivier .
JOURNAL OF HEPATOLOGY, 2018, 68 (04) :783-797
[63]  
NCCN, 2023, NCCN Guidelines Version 2.2023. Cancer-Related Fatigue
[64]   Current Status of Hepatic Arterial Infusion Chemotherapy [J].
Obi, Shuntaro ;
Sato, Shinpei ;
Kawai, Toshihiro .
LIVER CANCER, 2015, 4 (03) :188-199
[65]   Radiofrequency Ablation With or Without Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Prospective Randomized Trial [J].
Peng, Zhen-Wei ;
Zhang, Yao-Jun ;
Chen, Min-Shan ;
Xu, Li ;
Liang, Hui-Hong ;
Lin, Xiao-Jun ;
Guo, Rong-Ping ;
Zhang, Ya-Qi ;
Lau, Wan Yee .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04) :426-432
[66]   Recurrent Hepatocellular Carcinoma Treated with Sequential Transcatheter Arterial Chemoembolization and RF Ablation versus RF Ablation Alone: A Prospective Randomized Trial [J].
Peng, Zhen-Wei ;
Zhang, Yao-Jun ;
Liang, Hui-Hong ;
Lin, Xiao-Jun ;
Guo, Rong-Ping ;
Chen, Min-Shan .
RADIOLOGY, 2012, 262 (02) :689-700
[67]   Lenvatinib combined with transarterial chemoembolization as first-line treatment of advanced hepatocellular carcinoma: A phase 3, multicenter, randomized controlled trial [J].
Peng, Zhenwei ;
Fan, Wenzhe ;
Zhu, Bowen ;
Li, Jiaping ;
Kuang, Ming .
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[68]   Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy. [J].
Pinato, David J. ;
Murray, Sam M. ;
Forner, Alejandro ;
Kaneko, Takahiro ;
Fessas, Petros ;
Toniutto, Pierluigi ;
Minguez, Beatriz ;
Cacciato, Valentina ;
Avellini, Claudio ;
Diaz, Alba ;
Boyton, Rosemary J. ;
Altmann, Daniel M. ;
Goldin, Robert D. ;
Akarca, Ayse U. ;
Marafioti, Teresa ;
Mauri, Francesco A. ;
Casagrande, Edoardo ;
Grillo, Federica ;
Giannini, Edoardo ;
Bhoori, Sherrie ;
Mazzaferro, Vincenzo .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (09)
[69]   Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation [J].
Pompili, Maurizio ;
Francica, Giampiero ;
Ponziani, Francesca Romana ;
Iezzi, Roberto ;
Avolio, Alfonso Wolfango .
WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (43) :7515-7530
[70]   Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial [J].
Qin, Shukui ;
Chen, Minshan ;
Cheng, Ann-Lii ;
Kaseb, Ahmed ;
Kudo, Masatoshi ;
Lee, Han Chu ;
Yopp, Adam C. ;
Zhou, Jian ;
Wang, Lu ;
Wen, Xiaoyu ;
Heo, Jeong ;
Tak, Won Young ;
Nakamura, Shinichiro ;
Numata, Kazushi ;
Uguen, Thomas ;
Hsiehchen, David ;
Cha, Edward ;
Hack, Stephen P. ;
Lian, Qinshu ;
Ma, Ning ;
Spahn, Jessica H. ;
Wang, Yulei ;
Wu, Chun ;
Chow, Pierce K. H. .
LANCET, 2023, 402 (10415) :1835-1847